3 Must-Buy Stocks for June 27, 2025—Top Analysts’ Picks Revealed
Markets are buzzing—these three stocks just got the golden nod from Wall Street's sharpest minds.
Forget the usual suspects. We're talking about under-the-radar plays with explosive upside potential.
Analysts are doubling down as institutional money starts rotating. The smart money's betting big—are you?
(Bonus truth bomb: Because nothing says 'trustworthy investment advice' like a timestamped headline from the future.)
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.
Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
(HIVE) – HIVE Digital is a tech company that uses green energy to power data centers for Bitcoin mining and AI services. Yesterday, H.C. Wainwright analyst Mike Colonnese maintained a Buy rating on the stock and decreased the price target to $6 from $9 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 280.5%.
(TTD) – This is a technology company that provides a platform for advertisers to manage and optimize digital ad campaigns across web, mobile, and streaming channels. Yesterday, Evercore ISI analyst Mark Mahaney upgraded the rating to Buy and maintained a price target of $90 per share. Interestingly, 17 out of the 20 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 32.48%.
(SLDB) – Solid Biosciences is a biotech company that develops precision gene therapies for rare neuromuscular and cardiac diseases. Yesterday, Citi analyst Yigal Nochomovitz initiated a Buy rating on the stock with a price target of $14 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 253.4%.
Who Are the Top Analysts?
TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.
See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page.
Disclosure
